The Sunday Read: ‘Ozempic Could Crush the Jun...

The iconic actor on his thrillingly risky choices, on screen and off, and becoming a meme. Thoughts? Email us at theinterview@nytimes.com Watch our show on YouTube: youtube.com/@TheInterviewPodcast For transcripts and more, visit: nytimes.com/theinterview Subscribe today at nytim ...  Show more

A new major poll from The Times/Siena suggests that despite his seemingly unchecked power over the federal government and his own party, President Trump’s national support is crumbling to record lows and Democrats are poised to win back many of the key voters who got him into off ...  Show more

Snack-food companies have long shown their adaptability to changing diets. How could the rise of appetite-suppressing drugs and fears about ultra-processed foods change the food we consume? How hearing aids and other lifestyle choices can reduce your risk of dementia (11:00). And ...  Show more

DATA: https://www.leefang.com/p/sugary-soda-industrys-covert-influencer https://www.heart.org/en/healthy-living/company-collaboration/food-system-strategy/aha-industry-nutrition-forum/industry-nutrition-forum-members

Most people know that the Americ ...

Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.

Why GLP-1 Drugs Are in Demand 

The junk food industry is facing a major shake-up as consumer habits shift, weight-loss drugs like Ozempic gain traction, and government intervention ramps up. From declining snack sales at PepsiCo and Mondelez to Robert F. Kennedy Jr.’s crackdown on artificial additives and j ...